New tools and platforms emerge transforming disease diagnosis and treatment. Saga Diagnostics secured Medicare coverage for a sensitive molecular residual disease test for breast cancer monitoring, enhancing post-treatment surveillance. Seegene previewed the CURECA system, a fully automated PCR lab platform enabling 24/7 pathogen testing with high throughput, poised for global rollout. MD Anderson and Toppan Holdings partnered to commercialize organoid assays for personalized cancer drug screening, promising tailored therapies. Additionally, Danaher strengthened collaborative diagnostics efforts in oncology and neurology, integrating precision pathology and immunoassays for advanced clinical research and trials.